N-Zyme Biomedical raises $4.6M Series A (United States, Jul 2026)
$4.6M
US$4.6 Million Series AGenerated social card
Headline
N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development - Times Argus
About
N-Zyme Biomedical is focused on developing novel therapies for reflux disease, specifically through its pepsin inhibitor platform. The company aims to address significant unmet medical needs in conditions like laryngopharyngeal reflux and gastroesophageal reflux disease. This funding round will accelerate their Phase 2 clinical programs and further their innovative approach to treatment.
Article summary
N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development Times Argus
Founder
Franco Vigile
Co-Founder and Chief Executive Officer
Investors
Related rounds
| Aug 14, 2026 | MiiHealth AI | $2.8M | — | United States |
| Aug 14, 2026 | Alloy Robotics | $8.0M | Pre-seed | United States |
| Aug 14, 2026 | Zipline | $950.0M | Debt | United States |
| Aug 14, 2026 | InduPro | $77.0M | Series B | United States |